MagBioSense
Pioneering simple, one-step point-of-care diagnostics with laboratory-quality accuracy for rapid heart attack diagnosis in emergency settings
Pioneering simple, one-step point-of-care diagnostics with laboratory-quality accuracy for rapid heart attack diagnosis in emergency settings
MagBioSense is a healthcare startup founded in 2013, with a focus on pioneering simple, one-step point-of-care diagnostics for rapid heart attack diagnosis in emergency settings. The company aims to provide laboratory-quality accuracy in a convenient and quick manner. MagBioSense's technology simplifies the detection process by eliminating additional steps, enabling a straightforward, single-step procedure in a clinical setting. Their primary focus is on leveraging high sensitivity detection of cardiac biomarkers for the rapid diagnosis and exclusion of heart attacks in the Emergency Department. The most recent investment, a Seed Round investment, was secured on 31 December 2015 from Roy Oron. As a private medical device company, MagBioSense is dedicated to creating innovative diagnostic tools and assays that address the critical need for accurate and swift diagnosis in emergency healthcare situations.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 1 | Roy Oron | 31 Dec 2015 |
| Grant | $1.00M | - | 31 Dec 2015 | |
| Grant | $50.00K | 1 |
|
14 May 2013 |
No recent news or press coverage available for MagBioSense.
We care about your data, and we'd love to use cookies make your experience better.
